Want to join the conversation?
$BMY 2Q15 Call: Delivered 7% overall sales growth YoverY. For Opdivo, had three early study stops, significant data presented at ASCO, three filings, three approvals, and commercial launches in both US & Europe. In Europe, Opdivo was approved for squamous lung cancer in this week. Expects to complete filing of 57 data in US & Europe in this week.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?